TEM is integrating externally developed AI pathology into its ecosystem to improve risk prediction and personalize prostate ...

The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...

Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

But a practice called integrative medicine, which combines conventional cancer therapies with complementary and holistic treatments, is increasingly being used to manage the disease. While ...

GLP-1 receptor agonists may help mitigate progression of at least some obesity-related cancers, according to retrospective ...

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer ...

Prostate cancer is one of the top diagnoses for men with cancer, but early stages are tough to detect. “You know, maybe some ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...